JPRN-jRCTs031230338招募中2 期
Evaluation of [11C]NCGG401 as a PET imaging ligand for microglia in Alzheimer's diseases - NCGG401-AD
Kimura Yasuyuki0 个研究点目标入组 55 人开始时间: 2023年9月11日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 发起方
- 入组人数
- 55
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 50age old 至 ot applicable（—）
- 性别
- All
入选标准
- •1. Cognitively healthy subjects
- •1)Persons who the principal investigator or subinvestigator (hereinafter referred to as principal investigator, etc.) judges to be capable of understanding the contents of the explanatory document. 2) Persons who are cognitively healthy. 1) Persons who are cognitively healthy
- •2)Persons who voluntarily applied for the research and obtained written consent to participate in the research.
- •3)Men and women who are 50 years of age or older at the time of consent
- •4)Those whose MMSE score is 24 or higher
- •5)Subjects who scored 9 or higher on the WMS-R Logical Memory II for subjects with 16 or more years of education, 5 or higher for subjects with 10 to 15 years of education, and 3 or higher for subjects with 0 to 9 years of education.
- •2. Patients with Alzheimer's disease (including patients with less than moderate or mild cognitive impairment)
- •1)Persons who are judged by the principal investigator to be capable of understanding the consent document
- •2)Persons who have given written consent to participate in the research
- •3)Those who are accompanied by a research assistant who is able to grasp and evaluate the subject's situation, and who have obtained the consent of the research assistant.
- •4)Men and women who are 50 years of age or older at the time of obtaining consent
- •5)Patients with Alzheimer's disease of moderate severity or less and patients with mild cognitive impairment who meet the clinical diagnostic criteria of NIA-AA (2011)
- •3. Patients with temporal lobe epilepsy
- •1)Persons who are judged by the principal investigator to be capable of understanding the consent document
- •2)Persons who have given written consent to participate in the research
- •3)Men and women who are 50 years of age or older at the time of consent
- •4)Patients with a diagnosis of temporal lobe epilepsy
- •5)Patients who have been taking antiepileptic drugs for less than three month at the time of consent.
- •4. Glioma patients
- •1)Persons who are judged by the principal investigator to be able to understand the consent document
- •2)Persons who have given written consent to participate in the research
- •3)Men and women who are 50 years of age or older at the time consent is obtained
- •4)Those who have been diagnosed with gliomas.
排除标准
- •1. Cognitively normal subjects
- •1)Patients with developmental and mental health problems that may interfere with the examination
- •2)Those who have undergone a nuclear medicine examination within 6 months from the time of obtaining consent, from the viewpoint of radiation exposure in nuclear medicine examinations.
- •2. Patients with gliomas
- •1)Those who have undergone more than 50% tumor removal, virus-based gene therapy, radiation therapy, bevacizumab, steroids, or anticancer drugs as treatment for gliomas.
- •3. All subjects
- •1)Subjects with apparent abnormalities in the medical examination or blood/urine tests at the time of eligibility evaluation, who are judged by the principal investigator, etc. to be at higher than usual risk of adverse health effects due to the PET scan.
- •2)Subjects who are judged to be unable to suppress their body movements during the examination.
- •3)Persons with magnetic metals in the body (tattoos, tattoos including art makeup, pacemakers, etc.)
- •4)Patients with a strong fear of claustrophobia
- •5)Those with a history of drug allergy
- •6)Those who are pregnant or may be pregnant, and those who are breast-feeding
- •7)Subjects with serious complications or those who have a history of serious complications and are judged to be ineligible for this study by the investigators.
- •8)Those who are regularly taking steroidal and non-steroidal anti-inflammatory drugs or immunosuppressive drugs
- •9)Participation in a clinical research study involving another intervention, and who have participated in the study for less than one year from the time of the intervention to the time of obtaining consent.
- •10)Persons who do not consent to the storage of specimens in the Center's biobank.
- •11)Other subjects who are judged to be ineligible for this study by the principal investigator.
研究者
相似试验
进行中（未招募）
1 期
Efficacy and safety of [11C]NCGG401Alzheimer's diseaseJPRN-jRCTs031210249Kimura Yasuyuki9
招募中
不适用
A clinical imaging study using [18F]F-AraG PET to visualize Tumor infiltrating T-cell Activation in Non-small cell lung cancerlung cancerNL-OMON50793Vrije Universiteit Medisch Centrum10
进行中（未招募）
1 期
A PET imaging substudy within the VER-AT1D trial investigating the effects on beta cell massMedDRA version: 21.1Level: PTClassification code 10067584Term: Type 1 diabetes mellitusSystem Organ Class: 10027433 - Metabolism and nutrition disordersType 1 diabetes mellitusEUCTR2020-004966-20-FRRadboud University Medical Center30
已完成
不适用
[F-18]FDG and [C-11]Acetate PET/CT study for refractory diseasesJPRN-UMIN000023101Tokyo Medical and Dental University40
进行中（未招募）
1 期
PD-L1 PET imaging study during CAR T-cell therapyPatients with relapsed/refractory large B-cell lymphoma (LBCL) after two or more lines of therapy who fulfill the eligibility criteria for CD19-directed CAR T-cell therapy according the Immune Effector Cell Working Group Tumorboard.EUCTR2021-005192-39-NLniversity Medical Center Groningen20